<DOC>
	<DOCNO>NCT00003782</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving combination chemotherapy surgery may kill tumor cell remain follow surgery . It yet know regimen combination chemotherapy effective treating breast cancer positive axillary lymph node . PURPOSE : Randomized phase III trial compare effectiveness different regimen combination chemotherapy treat woman undergone surgery stage I , stage II , stage IIIA breast cancer positive axillary lymph node .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Women With Stage I , Stage II , Stage IIIA ( cT1-3 , N0-1 , M0 ) Breast Cancer Positive Axillary Lymph Nodes</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy adjuvant doxorubicin , cyclophosphamide , docetaxel give concurrently vs adjuvant doxorubicin cyclophosphamide follow docetaxel , term overall survival disease-free survival , woman breast cancer positive axillary lymph node . - Compare efficacy adjuvant doxorubicin docetaxel v regimens contain cyclophosphamide patient . - Compare toxic effect regimens patient . - Compare quality life patient treat regimen . ( Quality life substudy close accrual 7/20/01 . ) - Compare difference amenorrhea premenopausal woman treatment arm relationship symptom , quality life ( quality life substudy close accrual 7/20/01 ) , disease-free survival , overall survival . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , number positive node ( 1-3 v 4-9 v least 10 ) , sequential tamoxifen anastrozole administration ( yes v ) , type prior surgery radiotherapy plan ( mastectomy local regional radiotherapy v mastectomy local and/or regional radiotherapy v lumpectomy local radiotherapy v lumpectomy local regional radiotherapy ) . Patients randomize one three treatment arm . - Arm 1 : Patients receive doxorubicin IV 15 minute cyclophosphamide IV 30 minute every 21 day 4 course . Three week last dose combination , patient receive docetaxel IV 1 hour every 21 day 4 course . - Arm 2 : Patients receive doxorubicin IV 15 minute docetaxel IV 1 hour every 21 day 4 course . - Arm 3 : Patients receive doxorubicin IV 15 minute , cyclophosphamide IV 30 minute , docetaxel IV 1 hour every 21 day 4 course . Patients arm estrogen receptor-positive and/or progesterone receptor-positive receive oral tamoxifen daily 5 year begin within 3-12 week completion chemotherapy . Patients postmenopausal may receive alternative hormonal therapy discretion treat physician . Some patient may receive postmastectomy radiotherapy SWOG-S9927 NCIC-MA.20 recovery chemotherapy . Quality life menstrual history assess randomization , day 1 course 4 , 6 , 12 , 18 , 24 month . ( Quality life substudy close accrual 7/20/01 . ) Patients follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 5,300 patient accrue study within 4-5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive adenocarcinoma breast Confined breast ipsilateral axilla clinical exam Stage I , II , IIIA ( cT13 , N01 , M0 ) At least one axillary lymph node evidence tumor histologic exam Sentinel node biopsy allow follow axillary dissection No suspicious palpable node contralateral axilla palpable supraclavicular infraclavicular node , unless prove biopsy involve tumor No bilateral malignancy mass opposite breast , unless mass histologically proven benign Must undergone either prior total mastectomy axillary dissection ( modified radical mastectomy ) OR Prior lumpectomy axillary dissection Patients must receive radiotherapy randomization ( ) AND chemotherapy Margins must clear No ipsilateral lymph node fix one another structure ( N2 disease ) and/or positive nonaxillary lymph node ( intramammary node consider axillary node ) No histologically evident invasive tumor ductal carcinoma situ No diffuse tumor mammography would surgically amenable lumpectomy No dominant mass ipsilateral breast remnant unless one follow true : Histologically benign Surgically remove clear margin malignant No ulceration , erythema , infiltration skin underlie chest wall ( complete fixation ) , peau d'orange , skin edema magnitude Tethering dimple skin nipple inversion allow No metastatic disease Skeletal pain allow bone scan negative metastasis Hormone receptor status : Estrogen progesterone status determine PATIENT CHARACTERISTICS : Age : great equal 18 year Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : At least 10 year , exclude diagnosis cancer Hematopoietic : Absolute neutrophil count least 1,500/mm^3 ( may less , opinion investigator , represent ethnic racial variation ) Platelet count least 100,000/mm^3* NOTE : *If platelet count upper limit normal ( ULN ) , significant underlie hematologic disorder must exclude Hepatic : Bilirubin great ULN Alkaline phosphatase less 2.5 time ULN* SGOT less 1.5 time ULN* No nonmalignant systemic hepatic disease would preclude study participation NOTE : *Alkaline phosphatase SGOT great ULN Renal : Creatinine great normal No nonmalignant systemic renal disease would preclude study participation Cardiovascular : No nonmalignant systemic cardiovascular disease would preclude study participation LVEF least low limit normal ( LLN ) MUGA echocardiogram No active cardiac disease would preclude use doxorubicin docetaxel , include follow : Any prior myocardial infarction Angina pectoris require antianginal medication History congestive heart failure Cardiac arrhythmia require medication Severe conduction abnormality Valvular disease document cardiac function compromise Cardiomegaly chest xray ventricular hypertrophy EKG , unless LVEF least LLN Poorly control hypertension ( diastolic great 100 mm/Hg ) Hypertension well control medication allow Other : No grade 2 great peripheral neuropathy No prior malignancy within past 5 year except : Effectively treat squamous cell basal cell skin cancer Surgically treat carcinoma situ cervix Segmentally resect lobular carcinoma situ ipsilateral contralateral breast Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No nonmalignant systemic disease would preclude study participation No diabetes morning fast blood glucose 200 mg/dL great No psychiatric addictive disorder would preclude informed consent No contraindication corticosteroid would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy breast cancer Chemotherapy : No prior chemotherapy breast cancer No prior anthracyclines taxanes No concurrent investigational chemotherapy Endocrine therapy : No prior hormonal therapy breast cancer No concurrent hormonal birth control method hormonal therapy No concurrent raloxifene , include osteoporosis Concurrent lowdose topical estrogen form conjugate estrogen ring conjugate estrogen vaginal cream ( dose 0.3 mg 1/8 applicator apply vaginally 3 time week ) allow Radiotherapy : See Disease Characteristics No prior radiotherapy malignancy Surgery : See Disease Characteristics No 84 day since prior surgery breast cancer ( e.g. , lumpectomy , mastectomy , sentinel node biopsy , axillary dissection , reexcision lumpectomy margin ) Other : No prior systemic therapy malignancy No concurrent medication alter cardiac conduction ( e.g. , digitalis , beta blocker , calciumchannel blocker ) cardiac arrhythmia , angina , congestive heart failure ( allow administer reason [ e.g. , hypertension ] ) Concurrent bisphosphonates allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>